As a botanical drug that remains federally illegal, marijuana faces an uphill battle for acceptance from the U.S. Food and Drug Administration, which has approved very few cannabis-based drugs.
Moving marijuana from Schedule 1 to Schedule 3 of the Controlled Substances Act could help open the door to more traditional, phased drug trials, according to Dr. Jean Talleyrand.
ADVERTISEMENT
He is chief medical officer of the Clinical Endocannabinoid System Consortium (CESC), a California-based nonprofit that studies how people use marijuana products that are already on the market.
Rescheduling remains beyond the horizon, but Talleyrand believes marijuana researchers still have ways to acquire valuable data in the meantime.
“Our approach has been to go to the community and get information from the community about what
Read full article on Marijuana Business Daily
